... repair genes were recently reported in 8-12% of patients with metastatic castration-resistant prostatecancer (mCRPC... for therapies exploiting defective DNA repair using a liquid biopsy AbstractText: Patients with metastatic prostatecancer and germline DNA repair defects exhibit a poor response to standard hormonal therapies, but ... Keyword: Castration-resistant prostatecancer.
Oncology (4) Prostatic Neoplasms (4), Neoplasms (3), more mentions
AbstractText: Understanding the adverse effects of contemporary approaches to localized prostatecancer treatment could inform shared decision making AbstractText: To compare functional ... diagnosed in 2011-2012 with clinical stage cT1-2, localized prostatecancer, with prostate-specific antigen levels less than 50 ng/mL ... diagnosis AbstractText: Patient-reported function on the 26-item Expanded ProstateCancer Index Composite (EPIC) 36 months after enrollment.
Abstract: Purpose Men with localized prostatecancer often are treated with external radiotherapy (RT) over 8 to ... We conducted a multicenter randomized noninferiority trial in intermediate-risk prostatecancer (T1 to 2a, Gleason score ≤ 6, and prostate-specific antigen ... local or distant failure, or death as a result of prostatecancer.
AbstractText: Patients diagnosed with localized prostatecancer have to decide among treatment strategies that may differ in ... 1141 men (57% participation among eligible men) with newly diagnosed prostatecancer were enrolled from January 2011 through June 2013 in collaboration ... active surveillance AbstractText: Quality of life using the validated instrument ProstateCancer Symptom Indices was assessed at baseline (pretreatment) and 3, 12 ...
Oncology (6), Urology (3), Men's Health (3) Prostatic Neoplasms (5), Urinary Incontinence (3), Neoplasms (1), more mentions
Little is known about men with localized prostatecancer who seek second opinions, the reasons why, and the association ... care AbstractText: We surveyed men who were diagnosed with localized prostatecancer in the greater Philadelphia area from 2012 to 2014... models to evaluate the relationship between second opinions and definitive prostatecancer treatment and perceived quality of care AbstractText: A total of ...
Oncology (14) Neoplasms (8), Prostatic Neoplasms (6), more mentions
... RADS 4), or highly likely (PI-RADS 5) to be clinically significant (cs) prostatecancer (PCa) AbstractText: We retrospectively included 1057 patients having MRGB, between January 2012 and ... Prostate Imaging Reporting and Data System yields high detection rates of clinically significant prostatecancer Keyword: In-bore biopsy... Keyword: Prostatecancer.
Abstract: Metastasis-directed therapy is of interest for the management of oligometastatic prostatecancer. Improved imaging may help with patient selection, but the approach to metastatic prostatecancer of "catching 'em all", or "Pokemet", must be considered experimental..
... prescriptions are unknown AbstractText: To determine the long-term effects of different exercise modes on fatigue in prostatecancer patients undergoing ADT AbstractText: Between 2009 and 2012, 163 prostatecancer patients aged 43-90 y on ADT were randomised to exercise targeting the musculoskeletal system (impact loading ... Keyword: Prostatecancer.
Oncology (5) Prostatic Neoplasms (4), Neoplasms (1), more mentions
... salivary gland carcinomas with high grade transformation, low grade cribriform cystadenocarcinoma, and squamous cell carcinomas involving parotid. Furthermore, the observation that SDC shares AR expression with prostatecancer and apocrine breast cancer foresaw the discovery of common molecular alterations between SDC and these tumor types and draw attention to androgen deprivation therapy for SDC patients Keyword: Androgen receptor. Keyword: Apocrine.
Three recent recommendations provide examples of how the USPSTF has used these principles: the 2015 recommendation on screening for abnormal blood glucose and type 2 diabetes; the 2016 recommendation on screening for breast cancer; and the recommendation on screening for prostatecancer, which is currently in progress. A more comprehensive list of recommendations that includes considerations for specific populations is ...
Oncology (2), Endocrine Disorders (1) Diabetes Mellitus, Type 2 (1), Prostatic Neoplasms (1), Breast Neoplasms (1), more mentions
The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostatecancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study.
To date, AR-targeted drugs have been approved only for treatment of prostatecancer; however, AR-targeted treatment for breast cancer is an area of active investigation. Through review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-related pathways, the potential for AR-targeted therapies in breast cancer, and potential biomarkers ...
Oncology (10) Breast Neoplasms (9), Prostatic Neoplasms (1), more mentions
... key-pathophysiological features of MPB and may represent promising targets for the development of novel therapeutic options. The data provide molecular evidence that rather than being an isolated trait, MPB shares a substantial biological basis with numerous other human phenotypes and may deserve evaluation as an early prognostic marker, for example, for prostatecancer, sudden cardiac arrest and neurodegenerative disorders.
Oncology (1), Men's Health (1) Alopecia (2), Prostatic Neoplasms (1), Sudden Cardiac Arrest (1), more mentions